newsfilter
← Latest News
GlobeNewswire·

NGM Bio Announces Oral and Late-Breaking Poster Presentations Supporting Its Myeloid Reprogramming Portfolio at Upcoming 2022 AACR Annual Meeting

Oral presentation to showcase NGM Bio's in vitro and in vivo research demonstrating potential advantages of dual ILT2/ILT4 inhibition with NGM707, currently in Phase 1/2 trial Late-breaking poster presentations to highlight preclinical research support